论文部分内容阅读
目的探讨二肽基肽酶-4抑制剂西格列汀对初诊2型糖尿病(T2DM)患者胰岛β细胞功能和血清Chemerin水平的影响。方法将82例初诊T2DM患者按照数字随机表法分为两组,每组41例,对照组采用二甲双胍片治疗,观察组联用二甲双胍片西格列汀治疗,比较两组治疗前后体质量指数(BMI)、血糖、糖化血红蛋白(Hb Alc)、血压、血脂、稳态模型β细胞功能指数(HOMA-β)、稳态模型胰岛素抵抗指数(HOMA-IR)、脂肪因子chemerin、空腹胰岛素(FINS)变化情况。结果治疗后两组BMI、血压、FBG、Hb Alc、TC、TG、LDL-C、血清Chemerin水平FINS、HOMA-IR均较治疗前降低,且观察组均低于对照组,两组HDL-C、HOMA-β较治疗前升高,观察组高于对照组差异均有统计学意义(P<0.05,P<0.01)。结论 DPP-4抑制剂西格列汀可改善胰岛β细胞功能、降低血清Chemerin水平。
Objective To investigate the effect of dipeptidyl peptidase-4 inhibitor sitagliptin on pancreatic β-cell function and serum Chemerin level in newly diagnosed type 2 diabetic patients (T2DM). Methods 82 cases of newly diagnosed T2DM patients were divided into two groups according to the digital random table method, 41 cases in each group. The control group was treated with metformin tablets. The observation group was treated with metformin tablets and sitagliptin. The body mass index BMI, Hb Alc, blood pressure, blood lipids, homeostasis model β-cell function index (HOMA-β), homeostasis model insulin resistance index (HOMA-IR), adipokines chemerin, fasting insulin (FINS) Changes. Results After treatment, BMI, blood pressure, FBG, Hb Alc, TC, TG, LDL-C, serum Chemerin levels of FINS and HOMA-IR in both groups were lower than those before treatment, , HOMA-β increased compared with that before treatment, the difference between the observation group and the control group was statistically significant (P <0.05, P <0.01). Conclusions Sipagliptin, a DPP-4 inhibitor, can improve pancreatic β-cell function and decrease serum Chemerin levels.